HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries

Elena Nicod, Lieven Annemans, Anna Bucsics, Anne Lee, Sheela Upadhyaya and Karen Facey

Health Policy, 2019, vol. 123, issue 2, 140-151

Abstract: Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were identified in Advance-HTA. Since then, new initiatives have been developed to specifically address issues related to HTA of OMPs.

Keywords: Rare diseases; Technology assessment; Value of life; England; Scotland; Europe; Uncertainty (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851017300842
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:123:y:2019:i:2:p:140-151

DOI: 10.1016/j.healthpol.2017.03.009

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().